| Axillary Sampling as an Alternative Option for Complete Nodal Response in Triple Negative and HER2 Type Breast Cancer Patients after Neoadjuvant Chemotherapy |
| Chan Sub Park, M.D., Ph.D., Jeeyeon Lee, M.D., Ph.D., Jin Hyang Jung, M.D., Ph.D., Wan Wook Kim, M.D., Ph.D., Yee Soo Chae, M.D., Ph.D.1, Hye Jung Kim, M.D., Ph.D.2, Won Hwa Kim, M.D., Ph.D.2, Ji-Young Park, M.D., Ph.D.3, Jee Young Park, M.D., Ph.D.3, Soo Jung Lee, M.D., Ph.D.1, Mi Young Kim, M.D., Ph.D.4, Jung Dug Yang, M.D., Ph.D.5, Joon Seok Lee, M.D., Ph.D.5, Ho Yong Park, M.D., Ph.D. |
Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
1Department of Hemato-Oncology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
2Department of Radiology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
3Department of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
4Department of Radiation Oncology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
5Department of Plastic and Reconstructive Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea |
| Corresponding Author:
Ho Yong Park ,Tel: +82-53-200-2702, Fax: +82-53-200-2028, Email: phy123@knu.ac.kr |
|
Received: April 21, 2020 Revised: August 4, 2020 Accepted: August 22, 2020 |
|
|
Share : 
|
| ABSTRACT |
Purpose: In patients with locally advanced breast cancer, neoadjuvant chemotherapy is widely used. It has a distinct advantage in the downstaging of the primary tumor and provides important information about treatment response. With its increasing usage, concerns over the appropriate management of the axilla have emerged. In this study, we compared oncological outcomes of conventional axillary lymph node dissection (ALND) over axillary sampling (AS) with radiotherapy (RT) in patients who received neoadjuvant chemotherapy.
Methods: In this retrospective study, we included female patients with triple negative breast cancer (TNBC) and HER2 type breast cancer who underwent breast and axillary surgery after neoadjuvant chemotherapy between May 2011 to December 2016. A total of 89 patients’ medical records were eligible for analysis. We defined AS as removal of at least four axillary lymph nodes located near the sentinel lymph nodes without full exposure of the axillary vein, long thoracic nerve, and thoracodorsal nerve.
Results: The median follow-up period was 47.00 months. The disease-free survival was 69.66 months in the AS with RT group and 69.02 months in the ALND group (p=0.280). The invasive disease-free survival was 75.16 months in the AS with RT group and 78.44 months in the ALND group (p=0.218).
Conclusions: AS with radiotherapy might be a feasible surgical option in patients with TNBC and HER2 type breast cancer after neoadjuvant chemotherapy. |
| Keywords:
Breast neoplasms | Lymph node excision | Neoadjuvant therapy |
|
PDF Links
Full text via DOI
Download Citation 
E-Mail 
